Smart ring maker Oura agreed to buy primary care startup Counsel Health in a $625 million deal on Tuesday [1]. The Counsel Health acquisition brings an AI health platform and licensed medical doctors into Oura’s hardware ecosystem. The pact builds on a software link started in June to let ring wearers review body metrics with doctors. Both firms expect the purchase to close before late 2027.
Counsel Health Acquisition Terms
Oura agreed to pay $625 million for Counsel Health [1]. The buyout gives Oura full control of the startup, with Counsel chief executive Muthu Alagappan joining Oura as chief clinical AI officer alongside 70 startup employees, according to reporting from Bloomberg [2]. Both groups expect the deal to clear regulatory reviews before 2027 ends [1].
Counsel Health previously funded its clinical work through private venture rounds. Last year, venture capital firms Andreessen Horowitz, often called a16z, and GV led a $25 million Series A round for Counsel Health. Financial research group PitchBook estimates that Counsel Health secured $36 million in total capital before agreeing to the Counsel Health acquisition. Oura announced that Counsel will keep its current workplace contracts while signing new deals with outside employers. Counsel plans to offer its care model to employees who do not own an Oura ring, taking its AI health tools well past wearable buyers [1].
Leadership from both teams said the deal grew out of shared culture and months of product planning. “At Counsel, we’ve built medical AI around trust, safety and responsibility, keeping physicians in the loop for clinical decisions,” Alagappan said in a press release. He added that the two groups bonded over a joint mission as talks progressed [1].
Clinical AI and Doctor Chats
Counsel Health pairs AI chat tools with licensed human doctors. The software answers daily symptom questions, checks lab test data, and connects patients with a doctor when they need prescriptions or clinic referrals. Human doctors review all treatment plans [1].
Oura added Counsel Health tools to its mobile app in June. That initial release gave ring owners an easy way to chat about their daily sleep and heart numbers with a medical system. Now, Oura and Counsel plan to expand their joint platform into preventative care, acute visits, chronic illness care, and specialty doctor referrals. The expanded roadmap turns continuous ring metrics into actionable appointments, providing medical follow-up whenever body data shifts from normal baselines. Connecting ring sensors to doctor visits lets the software spot subtle body changes and help users seek medical advice before minor health problems turn serious [1].
Both companies want to turn body data into medical action. “Oura helps members understand their physiology and, with Counsel, they can take action on their health across a range of needs, from quick questions and prescriptions to lab results, chronic care, and referrals,” Oura CEO Tom Hale said in a press release. Alagappan said that Oura ring data gives doctors objective context, trended biometrics, and member engagement to deliver more informed care during visits [1].
Smart Ring Rivals
Oura has led the smart ring space for years, but rivals like RingConn and Ultrahuman sell competitive hardware that tests its market lead, as tracked by TechCrunch. Rival device makers sell rings at lower prices. In response, Oura plans to stand out by blending doctor visits into its software membership [1].
Fitness rings track daily body stats like skin temperature, sleep cycles, and heart rate variability, yet users often do not know what steps to take when numbers change. A sudden jump in temperature or an irregular heart reading can indicate an oncoming fever, heavy training, or simple stress. Without clinical help, members search online forums or book clinic visits to decode their data. Oura leaders believe that putting licensed doctors inside its app clears up that confusion, letting wearers share ongoing body trends with doctors who can review symptoms and prescribe drugs without delay. The software links raw sensor data with professional medical care [1].
Safety remains a core concern as AI enters clinical health. Patients reading online chats must know if the care is safe and legit. Counsel meets this demand by requiring licensed doctors to oversee all clinical decisions, so automated models never make diagnostic calls or write prescriptions alone [1].
Counsel Health Acquisition Goals
The Counsel Health acquisition moves Oura past consumer gadgets into primary medical care. By offering doctor chats, Oura can sell health plans to corporate employers and health networks seeking preventative care that lowers staff medical costs [1].
Venture funding in AI tools created large funding rounds in business software this year. While cloud tools saw deals like the Fal AI valuation doubling to 16 billion dollars, hardware makers are buying medical startups to gain clinical skills. Building a group of licensed doctors and compliant health code takes years of clinical trials and regulatory reviews. By buying an established startup, Oura avoids long development paths and gains an active clinical staff that already knows how to link chat tools with patient care. The acquisition speeds up Oura’s medical ambitions by several years.
Oura said that Counsel Health will continue serving its enterprise clients after the buyout closes. That independence lets Counsel sign new workplace partners while helping Oura spread its care model to patients outside ring buyers. Both teams plan to share software findings while keeping client contracts intact [1].
Revenue Growth and Delayed IPO
The deal comes after strong gains in ring sales and app subscriptions. Oura said its quarterly revenue grew 153 percent year-over-year to $533 million for the quarter ended September 30. For fiscal year 2026, Oura generated about $1.75 billion in revenue, which was 92 percent higher than the prior year [1].
The strong sales numbers follow a paused initial public offering. Just weeks before announcing the Counsel Health acquisition, Oura postponed its proposed $2.2 billion IPO indefinitely, citing uncertainty in the public IPO market. Leadership chose to delay the stock listing while using existing cash reserves to fund strategic buyouts. The move shows broader caution among tech firms waiting for calm market conditions before selling shares to public investors. Staying private gives Oura freedom to build clinical tools and grow its user base without managing quarterly earnings calls for public stock analysts, according to Bloomberg [1].
Investors valued Oura at $11 billion after a $900 million late-stage funding round in October 2025 [1]. With rising sales and private funding, Oura holds the cash needed to absorb Counsel’s 70 workers and invest in medical care. Oura can now expand its primary care plans on its own schedule [2].
- ONLINE NEWS Malik, A. (2026). Oura to acquire AI-native primary care startup Counsel Health for $625M. TechCrunch. [Article Link]
- ONLINE NEWS Gurman, M. (2026). Oura agrees to acquire AI and on-demand doctor tool Counsel Health for $625M. Bloomberg via Techmeme. [Article Link]
